All In Biotech

Drug Trial Radar · NCT05658484

A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

A Multicenter, Postmarketing Study of Dimethyl Fumarate (Tecfidera; BG00012) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Last checked: Nov 20, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Jun 9, 2023

Primary completion

Mar 27, 2025

Study completion Apr 12, 2025

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Dec 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to assess the efficacy of DMF in Chinese participants with RMS at Week 48. The secondary objectives of the study are to assess the efficacy and safety of DMF in Chinese participants with RMS.

Conditions

  • Multiple Sclerosis

Interventions

  • Dimethyl fumarateDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR)Time frame: Week 48

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, China

  • Xiangya Hospital Central South University

    Changsha, China

  • West China Hospital of Sichuan University

    Chengdu, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, China

  • The Third Affiliated Hospital of Sun Yat-Sen University

    Guangzhou, China

  • The Second Hospital of Hebei Medical University

    Hebei, China

  • The First People's Hospital of Yunnan Province

    Kunming, China

  • Renji Hospital, Shanghai Jiatong Uni. School of Medicine

    Shanghai, China

  • Huashan Hospital, Fudan University

    Shanghai, China

  • The First Hospital of China Medical University

    Shengyang, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, China

  • The First Affiliated Hospital of Shanxi Medical University

    Taiyuan, China

  • Tianjin Medical University General Hospital

    Tianjin, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China

  • Second Affiliated Hospital of Air Force Medical University

    Xi'an, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.